title: Endocrine and immune responses to resistance training in prostate cancer patients.
abstract: This study examined the effect of 20 weeks resistance training on a range of serum hormones and inflammatory markers at rest, and following acute bouts of exercise in prostate cancer patients undergoing androgen deprivation. Ten patients exercised twice weekly at high intensity for several upper and lower-body muscle groups. Neither testosterone nor prostate-specific antigen changed at rest or following an acute bout of exercise. However, serum growth hormone (GH), dehydroepiandrosterone (DHEA), interleukin-6, tumor necrosis factor-alpha and differential blood leukocyte counts increased (P < 0.05) following acute exercise. Resistance exercise does not appear to compromise testosterone suppression, and acute elevations in serum GH and DHEA may partly underlie improvements observed in physical function.
authors.affiliation: Vario Health Institute, Edith Cowan University, Joondalup, Western Australia, Australia. d.galvao@ecu.edu.au
authors.forename: D A
authors.initials: DA
authors.lastname: Galvão
authors.forename: K
authors.initials: K
authors.lastname: Nosaka
authors.forename: D R
authors.initials: DR
authors.lastname: Taaffe
authors.forename: J
authors.initials: J
authors.lastname: Peake
authors.forename: N
authors.initials: N
authors.lastname: Spry
authors.forename: K
authors.initials: K
authors.lastname: Suzuki
authors.forename: K
authors.initials: K
authors.lastname: Yamaya
authors.forename: M R
authors.initials: MR
authors.lastname: McGuigan
authors.forename: L J
authors.initials: LJ
authors.lastname: Kristjanson
authors.forename: R U
authors.initials: RU
authors.lastname: Newton
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology*; D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use; D015415:Biomarkers; D016723:Bone Remodeling; D016207:Cytokines / Q000097:blood*; D003687:Dehydroepiandrosterone / Q000097:blood; D005081:Exercise Therapy / Q000009:adverse effects; D005500:Follow-Up Studies; D006728:Hormones / Q000097:blood*; D019382:Human Growth Hormone / Q000097:blood; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood*; D015850:Interleukin-6 / Q000097:blood; D007958:Leukocyte Count; D008297:Male; D009119:Muscle Contraction; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology*; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D014891:Weight Lifting / Q000502:physiology*
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D015415:Biomarkers; D016207:Cytokines; D006728:Hormones; C508600:IL6 protein, human; D018836:Inflammation Mediators; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D019382:Human Growth Hormone; D003687:Dehydroepiandrosterone; D017430:Prostate-Specific Antigen